Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free SPEC Stock Alerts

Spectaire (SPEC) Competitors

Spectaire logo
$0.0005 0.00 (0.00%)
As of 09:30 AM Eastern
Compare

SPEC vs. TBIO, THMO, HTGMQ, OLITW, and PRENW

Should you buy Spectaire stock or one of its competitors? MarketBeat compares Spectaire with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spectaire include Telesis Bio (TBIO), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), and Prenetics Global (PRENW). These companies are all part of the "measuring and control equipment" industry.

How does Spectaire compare to Telesis Bio?

Telesis Bio (NASDAQ:TBIO) and Spectaire (NASDAQ:SPEC) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Telesis Bio has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, Spectaire has a beta of -6.36, meaning that its share price is 736% less volatile than the broader market.

In the previous week, Telesis Bio's average media sentiment score of 0.00 equaled Spectaire'saverage media sentiment score.

Company Overall Sentiment
Telesis Bio Neutral
Spectaire Neutral

Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Telesis Bio's return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
Telesis Bio-336.59% N/A -61.89%
Spectaire N/A -81.22%304.57%

37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 26.5% of Spectaire shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spectaire has lower revenue, but higher earnings than Telesis Bio. Spectaire is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A
SpectaireN/AN/A$8.95M-$0.30N/A

Summary

Telesis Bio and Spectaire tied by winning 5 of the 10 factors compared between the two stocks.

How does Spectaire compare to ThermoGenesis?

ThermoGenesis (NASDAQ:THMO) and Spectaire (NASDAQ:SPEC) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

5.8% of ThermoGenesis shares are held by institutional investors. Comparatively, 26.5% of Spectaire shares are held by institutional investors. 78.0% of ThermoGenesis shares are held by insiders. Comparatively, 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ThermoGenesis has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Spectaire has a beta of -6.36, indicating that its stock price is 736% less volatile than the broader market.

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Spectaire'saverage media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Spectaire Neutral

Spectaire has lower revenue, but higher earnings than ThermoGenesis. Spectaire is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
SpectaireN/AN/A$8.95M-$0.30N/A

ThermoGenesis' return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Spectaire N/A -81.22%304.57%

Summary

ThermoGenesis beats Spectaire on 5 of the 9 factors compared between the two stocks.

How does Spectaire compare to HTG Molecular Diagnostics?

Spectaire (NASDAQ:SPEC) and HTG Molecular Diagnostics (NASDAQ:HTGMQ) are both measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

HTG Molecular Diagnostics' return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
SpectaireN/A -81.22% 304.57%
HTG Molecular Diagnostics N/A N/A N/A

Spectaire has higher earnings, but lower revenue than HTG Molecular Diagnostics. Spectaire is trading at a lower price-to-earnings ratio than HTG Molecular Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectaireN/AN/A$8.95M-$0.30N/A
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A

26.5% of Spectaire shares are held by institutional investors. 25.4% of Spectaire shares are held by company insiders. Comparatively, 2.6% of HTG Molecular Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Spectaire has a beta of -6.36, meaning that its stock price is 736% less volatile than the broader market. Comparatively, HTG Molecular Diagnostics has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market.

In the previous week, Spectaire's average media sentiment score of 0.00 equaled HTG Molecular Diagnostics'average media sentiment score.

Company Overall Sentiment
Spectaire Neutral
HTG Molecular Diagnostics Neutral

Summary

Spectaire beats HTG Molecular Diagnostics on 5 of the 9 factors compared between the two stocks.

How does Spectaire compare to OmniLit Acquisition?

Spectaire (NASDAQ:SPEC) and OmniLit Acquisition (NASDAQ:OLITW) are both measuring and control equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

In the previous week, Spectaire's average media sentiment score of 0.00 equaled OmniLit Acquisition'saverage media sentiment score.

Company Overall Sentiment
Spectaire Neutral
OmniLit Acquisition Neutral

26.5% of Spectaire shares are owned by institutional investors. 25.4% of Spectaire shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

OmniLit Acquisition's return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
SpectaireN/A -81.22% 304.57%
OmniLit Acquisition N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectaireN/AN/A$8.95M-$0.30N/A
OmniLit AcquisitionN/AN/AN/AN/AN/A

Summary

Spectaire beats OmniLit Acquisition on 3 of the 4 factors compared between the two stocks.

How does Spectaire compare to Prenetics Global?

Spectaire (NASDAQ:SPEC) and Prenetics Global (NASDAQ:PRENW) are both measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Prenetics Global's return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
SpectaireN/A -81.22% 304.57%
Prenetics Global N/A N/A N/A

Spectaire has higher earnings, but lower revenue than Prenetics Global.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectaireN/AN/A$8.95M-$0.30N/A
Prenetics Global$120.07MN/AN/AN/AN/A

26.5% of Spectaire shares are held by institutional investors. 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Prenetics Global had 1 more articles in the media than Spectaire. MarketBeat recorded 1 mentions for Prenetics Global and 0 mentions for Spectaire. Prenetics Global's average media sentiment score of 1.87 beat Spectaire's score of 0.00 indicating that Prenetics Global is being referred to more favorably in the news media.

Company Overall Sentiment
Spectaire Neutral
Prenetics Global Very Positive

Summary

Prenetics Global beats Spectaire on 4 of the 7 factors compared between the two stocks.

Get Spectaire News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

SPEC vs. The Competition

Export
MetricSpectaireMeasuring & controlling devices IndustryComputer SectorNASDAQ Exchange
Market Cap$9K$94.67M$40.03B$12.37B
Dividend YieldN/A11.22%3.16%5.66%
P/E Ratio0.006.0281.6124.65
Price / SalesN/A8.23635.18167.03
Price / CashN/A8.3849.0237.92
Price / Book0.001.289.956.81
Net Income$8.95M$7.16M$1.07B$337.32M
7 Day PerformanceN/A-0.65%1.27%2.37%
1 Month PerformanceN/A-1.82%7.01%4.25%
1 Year PerformanceN/A190.10%163.90%32.60%

Spectaire Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
Spectaire
N/A$0.00
flat		N/A-54.5%$9KN/AN/A8
TBIO
Telesis Bio
N/A$0.00
flat		N/A-98.0%$2K$225.09MN/A200
THMO
ThermoGenesis
N/A$0.00
flat		N/AN/A$1K$9.61MN/A40
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/A$0.00$6.37MN/A90
OLITW
OmniLit Acquisition
N/A$1.67
flat		N/AN/A$0.00N/AN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SPEC) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel